The rapidly growing numbers of monoclonal antibodies (mAbs), fusion proteins and biosimilars produced by the pharma industry have greatly improved patient care and resulted in a proliferation of innovative treatment options. To date, there are over 100 biosimilars [1, 2], 162 mAbs [3] and over 11 fusion proteins [4] approved for therapeutic use. These new therapeutic proteins are often more...
Customized solutions for biologics development: leveraging adaptive platforms to meet customer needs
read more
